Apogee Therapeutics (APGE) Receivables - Other (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Receivables - Other data on file, last reported at $7.3 million in Q1 2026.

• Quarterly Receivables - Other rose 45.3% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 45.3% YoY) and the FY2025 annual result came in at $6.0 million, up 26.91% from the prior year.
• Receivables - Other improved to $7.3 million in Q1 2026 per APGE's latest filing, from $6.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $7.3 million in Q1 2026 and bottomed at $1.2 million in Q4 2023.
• The 4-year median for Receivables - Other is $4.7 million (2024), against an average of $4.7 million.
• The widest annual swing landed in 2024, when Receivables - Other jumped 286.9%; it then retreated 6.16% in 2025.
• Tracing APGE's Receivables - Other over 4 years: stood at $1.2 million in 2023, then jumped by 286.9% to $4.7 million in 2024, then climbed by 26.91% to $6.0 million in 2025, then advanced by 22.14% to $7.3 million in 2026.
• Per Business Quant, the three latest APGE Receivables - Other figures stand at $7.3 million (Q1 2026), $6.0 million (Q4 2025), and $4.5 million (Q3 2025).

Peer Comparison